South Korea · Delayed Price · Currency is KRW Cellumed Statistics
Total Valuation
Cellumed has a market cap or net worth of KRW 83.94 billion. The enterprise value is 91.55 billion.
| Market Cap | 83.94B |
| Enterprise Value | 91.55B |
Important Dates
The last earnings date was Friday, August 28, 2026.
| Earnings Date | Aug 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Cellumed has 83.19 million shares outstanding. The number of shares has increased by 29.92% in one year.
| Current Share Class | 83.19M |
| Shares Outstanding | 83.19M |
| Shares Change (YoY) | +29.92% |
| Shares Change (QoQ) | +8.14% |
| Owned by Insiders (%) | 0.32% |
| Owned by Institutions (%) | 1.51% |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 25.41.
| PE Ratio | 25.41 |
| Forward PE | n/a |
| PS Ratio | 0.70 |
| PB Ratio | 3.29 |
| P/TBV Ratio | 3.30 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 34.22 |
| EV / Sales | 0.76 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.33, with a Debt / Equity ratio of 0.35.
| Current Ratio | 1.33 |
| Quick Ratio | 0.46 |
| Debt / Equity | 0.35 |
| Debt / EBITDA | 7.83 |
| Debt / FCF | -2.31 |
| Interest Coverage | 0.40 |
Financial Efficiency
Return on equity (ROE) is 15.55% and return on invested capital (ROIC) is 1.59%.
| Return on Equity (ROE) | 15.55% |
| Return on Assets (ROA) | 0.32% |
| Return on Invested Capital (ROIC) | 1.59% |
| Return on Capital Employed (ROCE) | 1.37% |
| Weighted Average Cost of Capital (WACC) | 11.59% |
| Revenue Per Employee | 2.14B |
| Profits Per Employee | 47.77M |
| Employee Count | 56 |
| Asset Turnover | 1.63 |
| Inventory Turnover | 17.05 |
Taxes
| Income Tax | -38.96M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.93% in the last 52 weeks. The beta is 1.40, so Cellumed's price volatility has been higher than the market average.
| Beta (5Y) | 1.40 |
| 52-Week Price Change | -29.93% |
| 50-Day Moving Average | 1,532.94 |
| 200-Day Moving Average | 991.65 |
| Relative Strength Index (RSI) | 39.32 |
| Average Volume (20 Days) | 1,769,414 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cellumed had revenue of KRW 119.81 billion and earned 2.68 billion in profits. Earnings per share was 39.71.
| Revenue | 119.81B |
| Gross Profit | 13.25B |
| Operating Income | 372.01M |
| Pretax Income | 2.60B |
| Net Income | 2.68B |
| EBITDA | 1.14B |
| EBIT | 372.01M |
| Earnings Per Share (EPS) | 39.71 |
Balance Sheet
The company has 5.10 billion in cash and 8.91 billion in debt, with a net cash position of -3.81 billion or -45.78 per share.
| Cash & Cash Equivalents | 5.10B |
| Total Debt | 8.91B |
| Net Cash | -3.81B |
| Net Cash Per Share | -45.78 |
| Equity (Book Value) | 25.48B |
| Book Value Per Share | 306.10 |
| Working Capital | 15.02B |
Cash Flow
In the last 12 months, operating cash flow was -3.65 billion and capital expenditures -200.29 million, giving a free cash flow of -3.85 billion.
| Operating Cash Flow | -3.65B |
| Capital Expenditures | -200.29M |
| Depreciation & Amortization | 764.99M |
| Net Borrowing | -1.72B |
| Free Cash Flow | -3.85B |
| FCF Per Share | -46.31 |
Margins
Gross margin is 11.06%, with operating and profit margins of 0.31% and 2.23%.
| Gross Margin | 11.06% |
| Operating Margin | 0.31% |
| Pretax Margin | 2.17% |
| Profit Margin | 2.23% |
| EBITDA Margin | 0.95% |
| EBIT Margin | 0.31% |
| FCF Margin | n/a |
Dividends & Yields
Cellumed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -29.92% |
| Shareholder Yield | -29.92% |
| Earnings Yield | 3.19% |
| FCF Yield | -4.59% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 28, 2017. It was a reverse split with a ratio of 0.1.
| Last Split Date | Apr 28, 2017 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Cellumed has an Altman Z-Score of -0.06 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.06 |
| Piotroski F-Score | 4 |